Vaccines containing ribavirin and methods of use thereof
The present invention relates to compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans. More particularly, the use of Ribavirin as an adjuvant to a vaccine protocol and compositions having Ribavirin and an antigen are described.
1. A method of increasing the titer of hepatitis viral antigen-specific IgG antibodies in a subject in need thereof consisting essentially of providing, in a single administration, an immunogenic composition that comprises an effective amount of ribavirin and said hepatitis viral antigen to said subject.
2. The method of claim 1 , further comprising identifying said subject as one in need of an increase in titer of IgG antibodies that are specific for said hepatitis viral antigen.
3. The method of claim 1 , further comprising measuring the increase in the titer of hepatitis viral antigen-specific IgG antibodies in a subject.
4. The method of claim 2 , further comprising measuring the increase in the titer of hepatitis viral antigen-specific IgG antibodies in said subject.
5. The method of claim 1 , wherein said hepatitis antigen is an antigen from hepatitis B virus or hepatitis C virus.
6. The method of claim 2 , wherein said hepatitis antigen is an antigen from hepatitis B virus or hepatitis C virus.
7. The method of claim 3 , wherein said hepatitis antigen is an antigen from hepatitis B virus or hepatitis C virus.
8. The method of claim 4 , wherein said hepatitis antigen is an antigen from hepatitis B virus or hepatitis C virus.
9. The method of claim 1 , wherein said viral antigen comprises a hepatitis C viral antigen.
10. The method of claim 2 , wherein said viral antigen comprises a hepatitis C viral antigen.
11. The method of claim 3 , wherein said viral antigen comprises a hepatitis C viral antigen.
12. The method of claim 4 , wherein said viral antigen comprises a hepatitis C viral antigen.
13. The method of claim 1 , wherein said viral antigen comprises an NS3 antigen.
14. The method of claim 2 , wherein said viral antigen comprises an NS3 antigen.
15. The method of claim 3 , wherein said viral antigen comprises an NS3 antigen.
16. The method of claim 4 , wherein said viral antigen comprises an NS3 antigen.
17. The method of claim 1 , wherein said viral antigen comprises an NS4A antigen.
18. The method of claim 2 , wherein said viral antigen comprises an NS4A antigen.
19. The method of claim 3 , wherein said viral antigen comprises an NS4A antigen.
20. The method of claim 4 , wherein said viral antigen comprises an NS4A antigen.
21. The method of claim 1 , wherein said immunogenic composition is provided to said subject transdermally.
22. The method of claim 1 , wherein said immunogenic composition is provided to said subject intranasally.
23. The method of claim 1 , wherein said immunogenic composition comprises an oil.
24. The method of claim 1 , wherein said immunogenic composition is formulated for use with an injection device.
25. The method of claim 24 , wherein said injection device is an electrical injection device.
26. The method of claim 24 , wherein said injection device is a needleless injection device.
27. A method of producing a T cell response to a hepatitis viral antigen in a subject in need thereof consisting essentially of providing, in a single administration, an immunogenic composition that comprises an effective amount of ribavirin and said hepatitis viral antigen to said subject.
28. The method of claim 27 , further comprising identifying said subject as one in need of a T cell response to said hepatitis viral antigen.
29. The method of claim 27 , further comprising measuring the T cell response to said hepatitis viral antigen.
30. The method of claim 28 , further comprising measuring the T cell response to said hepatitis viral antigen.
31. The method of claim 27 , wherein said hepatitis antigen is an antigen from hepatitis B virus or hepatitis C virus.
32. The method of claim 28 , wherein said hepatitis antigen is an antigen from hepatitis B virus or hepatitis C virus.
33. The method of claim 29 , wherein said hepatitis antigen is an antigen from hepatitis B virus or hepatitis C virus.
34. The method of claim 30 , wherein said hepatitis antigen is an antigen from hepatitis B virus or hepatitis C virus.
35. The method of claim 27 , wherein said viral antigen comprises a hepatitis C viral antigen.
36. The method of claim 28 , wherein said viral antigen comprises a hepatitis C viral antigen.
37. The method of claim 29 , wherein said viral antigen comprises a hepatitis C viral antigen.
38. The method of claim 30 , wherein said viral antigen comprises a hepatitis C viral antigen.
39. The method of claim 27 , wherein said viral antigen comprises an NS3 antigen.
40. The method of claim 28 , wherein said viral antigen comprises an NS3 antigen.
41. The method of claim 29 , wherein said viral antigen comprises an NS3 antigen.
42. The method of claim 30 , wherein said viral antigen comprises an NS3 antigen.
43. The method of claim 27 , wherein said viral antigen comprises an NS4A antigen.
44. The method of claim 28 , wherein said viral antigen comprises an NS4A antigen.
45. The method of claim 29 , wherein said viral antigen comprises an NS4A antigen.
46. The method of claim 30 , wherein said viral antigen comprises an NS4A antigen.
47. The method of claim 27 , wherein said immunogenic composition is provided to said subject transdermally.
48. The method of claim 27 , wherein said immunogenic composition is provided to said subject intranasally.
49. The method of claim 27 , wherein said immunogenic composition comprises an oil.
50. The method of claim 27 , wherein said immunogenic composition is formulated for use with an injection device.
51. The method of claim 50 , wherein said injection device is an electrical injection device.
52. The method of claim 50 , wherein said injection device is a needleless injection device.